Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $42.2 million.

  • Zenas BioPharma's Shares Outstanding (Diluted Average) rose 44768.78% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 44768.78%. This contributed to the annual value of $13.2 million for FY2024, which is 76201.34% up from last year.
  • Zenas BioPharma's Shares Outstanding (Diluted Average) amounted to $42.2 million in Q3 2025, which was up 44768.78% from $41.9 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Shares Outstanding (Diluted Average) ranged from a high of $42.2 million in Q3 2025 and a low of $1.5 million during Q4 2023
  • Over the past 3 years, Zenas BioPharma's median Shares Outstanding (Diluted Average) value was $10.4 million (recorded in 2024), while the average stood at $18.9 million.
  • Over the last 5 years, Zenas BioPharma's Shares Outstanding (Diluted Average) had its largest YoY gain of 258973.37% in 2025, and its largest YoY loss of 44768.78% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Shares Outstanding (Diluted Average) stood at $1.5 million in 2023, then surged by 762.01% to $13.2 million in 2024, then soared by 219.41% to $42.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $42.2 million for Q3 2025, versus $41.9 million for Q2 2025 and $41.8 million for Q1 2025.